Skip to main content
Terns Pharmaceuticals, Inc. logo

Terns Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · TERN ISIN · US8808811074 LEI · 254900S1ZDQMF4MYP709 US Professional, scientific and technical activities
Filings indexed 406 across all filing types
Latest filing 2025-04-29 Annual Report
Country US United States of America
Listing US TERN

About Terns Pharmaceuticals, Inc.

https://ternspharma.com/

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops a portfolio of small-molecule product candidates for serious diseases, with a focus on oncology and obesity. The company's strategy is to innovate upon de-risked, clinically validated mechanisms of action to create therapies with superior efficacy, safety, and convenience profiles. Its lead product candidate, TERN-701, is an oral, allosteric BCR-ABL inhibitor in development for the treatment of chronic myeloid leukemia (CML). Terns aims to address significant unmet medical needs by improving upon existing treatments.

Recent filings

Filing Released Lang Actions
ARS
Annual Report
2025-04-29 English
DEFA14A
Regulatory Filings
2025-04-29 English
DEF 14A
Proxy Solicitation & Information Statement
2025-04-29 English
PRIMARY DOCUMENT
Director's Dealing
2025-04-03 English
S-8
Regulatory Filings
2025-03-20 English
10-K
Annual Report FY 2024
2025-03-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.